Curocell Inc. Logo

Curocell Inc.

Biotech developing enhanced CAR-T therapies for cancer using its OVIS™ platform.

372320 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
대전광역시 유성구 국제과학16로 11, 대전광역시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Curocell Inc. is a clinical-stage biotechnology company specializing in the research and development of Chimeric Antigen Receptor T-cell (CAR-T) therapies for cancer. A pioneer in South Korea, the company developed Limkato, the nation's first CAR-T therapy to complete clinical trials and be submitted for regulatory approval. Curocell's key innovation is its proprietary OVIS™ platform technology, which is engineered to enhance the efficacy and persistence of CAR-T cells by overcoming immune checkpoint-induced exhaustion. The company aims to address the limitations of existing immunotherapies and provide new treatment options for cancer patients, supported by its state-of-the-art GMP manufacturing facility.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Curocell Inc. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-17 00:00
Share Issue/Capital Change
주요사항보고서(전환사채권발행결정)
Korean 75.9 KB
2025-08-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-08-13 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.6 MB
2025-08-08 00:00
Legal Proceedings Report
투자판단관련주요경영사항(임상시험계획변경승인신청) (CRC01(안발캅타젠오토류셀, 안발셀)의 B세포 급성 림프모구성 성인…
Korean 12.5 KB
2025-08-04 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-08-04 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 101.7 KB
2025-08-01 00:00
Regulatory News Service
투자판단관련주요경영사항(임상시험계획승인신청등결정) (CD19 CAR-T 치료제 CRC01의 전신 홍반성 루푸스 제1,2…
Korean 12.0 KB

Automate Your Workflow. Get a real-time feed of all Curocell Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Curocell Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
TOWA PHARMACEUTICAL CO.,LTD. Logo
Manufactures and markets high-quality, accessible generic drugs for various therapeutic areas.
Japan 4553
TSUMURA & CO. Logo
A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.
Japan 4540
TURK İLAÇ VE SERUM SANAYİ A.Ş. Logo
Turkish producer of pharmaceuticals, specializing in IV solutions and vaccines for hospitals.
Türkiye TRILC
UCB Logo
UCB
Biopharma firm developing treatments for severe neurological and immunological diseases.
Belgium UCB
Develops biopharma therapies for endocrinology, ophthalmology, and dermatology needs.
Hong Kong N/A
UNION KOREA PHARM CO.,Ltd Logo
Develops and manufactures prescription drugs like antibiotics and analgesics for global markets.
South Korea 080720
Univo Pharmaceuticals Ltd. Logo
Vertically integrated biopharma firm developing medical cannabis treatments with a focus on CNS.
Israel UNVO-M
Valbiotis Logo
Develops clinically tested, plant-based supplements for metabolic & cardiovascular health.
France ALVAL
Valneva SE Logo
Develops and commercializes vaccines for infectious diseases like chikungunya, Lyme, and Zika.
France VLA
Vaxcell-Bio Therapeutics Logo
Develops CAR-T and CAR-NK immunotherapies for solid tumors and canine lymphoma.
South Korea 323990

Talk to a Data Expert

Have a question? We'll get back to you promptly.